Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
Price : $35 *
At a glance
- Drugs Decitabine (Primary) ; REC 2282 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.